Glimepiride Teva Uk

Glimepiride Teva Uk is an oral tablet that contains the active ingredient glimepiride, a second‑generation sulfonylurea used to manage blood glucose. It is manufactured for the EU market and is available by prescription only. The tablet formulation is designed for once‑daily dosing to help control hyperglycaemia in adults with type 2 diabetes mellitus.

Glimepiride Teva Uk is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive diabetes management plan that includes diet and exercise.

- Improves glycaemic control when used alone or in combination with other oral antidiabetic agents. - May be prescribed when metformin alone does not achieve target HbA1c levels. - Suitable for adult patients with adequate pancreatic beta‑cell function. - Can be used in patients who require a once‑daily oral therapy. - Often considered after lifestyle modifications have been implemented.

Glimepiride Teva Uk may cause a range of side effects, most of which are mild to moderate in severity.

Common: - Hypoglycaemia (low blood sugar) - Nausea or abdominal discomfort - Headache - Dizziness - Weight gain - Skin rash or itching

Serious: - Severe hypoglycaemia leading to loss of consciousness - Allergic reactions such as angio‑edema or Stevens‑Johnson syndrome - Hepatic dysfunction - Hematologic abnormalities (e.g., leukopenia, thrombocytopenia)

Before starting Glimepiride Teva Uk, certain precautions should be considered to ensure safe use.

- Assess renal and hepatic function; dose adjustment may be required. - Use cautiously in elderly patients due to increased risk of hypoglycaemia. - Contraindicated in patients with known sulfonylurea hypersensitivity. - Monitor blood glucose regularly, especially when initiating therapy or changing dose. - Pregnancy category B: discuss risks and benefits with a healthcare provider. - Avoid use in patients with severe cardiac disease without medical supervision.

Glimepiride Teva Uk can interact with several medicines, affecting its efficacy or safety.

Avoid: - Other sulfonylureas or insulin, which may increase hypoglycaemia risk. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels. - MAO‑B inhibitors, which may potentiate hypoglycaemic effects.

Use with caution: - Beta‑blockers, which may mask hypoglycaemia symptoms. - Thiazide diuretics, which can affect glucose tolerance. - Corticosteroids, which may increase blood glucose and require dose adjustments. - Alcohol, as it can potentiate hypoglycaemia.